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Countries
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Stephen R. Cole, PhD, Steven Meshnick, MD, PhD, and Stephen J. Rogerson, MBBS, DTM&H, FRACP, PhD, for the Maternal Malaria and
Malnutrition (M3) Initiative
Objectives. To estimate the impact of hypothetical antimalarial and nutritional in-
terventions (which reduce the prevalence of low midupper arm circumference [MUAC])
on the incidence of low birth weight (LBW).
Methods. We analyzed data from 14633 pregnancies from 13 studies conducted
across Africa and the Western Pacific from 1996 to 2015. We calculated population
intervention effects for increasing intermittent preventive therapy in pregnancy (IPTp),
full coverage with bed nets, reduction in malaria infection at delivery, and reductions in
the prevalence of low MUAC.
Results. We estimated that, compared with observed IPTp use, administering 3 or
more doses of IPTp to all women would decrease the incidence of LBW from 9.9% to
6.9% (risk difference = 3.0%; 95% confidence interval = 1.7%, 4.0%). The intervention
effects for eliminatingmalaria at delivery, increasing bed net ownership, and decreasing
low MUAC prevalence were all modest.
Conclusions. Increasing IPTp uptake to at least 3 doses could decrease the incidence of
LBW in malaria-endemic countries. The impact of IPTp on LBW was greater than the
effect of prevention of malaria, consistent with a nonmalarial effect of IPTp, mea-
surement error, or selection bias. (Am J Public Health. 2018;108:399–406. doi:10.2105/
AJPH.2017.304251)
Low birth weight (LBW; < 2500 g)remains a significant global health con- malaria-endemic countries, up to 1 in 4pregnant women are infected with malaria,
while up to 20% of women of childbearing
age in LMICs suffer undernutrition (body
mass index [BMI; defined as weight in ki-
lograms divided by the square of height in
meters] < 18.5).2,5,7 Although these 2 factors
are highly prevalent in LMICs, interventions
for them are often evaluated independently.
Our group, the Maternal Malaria and Mal-
nutrition (M3) Initiative, has endeavored to
better understand this coburden of malaria
infection and malnutrition during pregnancy.
Specifically, in a recent study in which we
used data pooled from 13 studies across Africa
and the Western Pacific, we found that
women who were both infected with malaria
and malnourished were at greater risk of
delivering a LBW infant than their un-
infected, well-nourished counterparts.
However, there was no conclusive evidence
of synergistic interaction between the 2 risk
factors for LBW (i.e., the effects of malaria
infection and nutritional status of the mother
on LBW were independent of each other).8
Although results from this study were
informative for furthering our understanding
of the biological mechanisms that affect fetal
growth and development, policymakers
would benefit from knowing howmany cases
of LBW could be prevented by interventions
targeting malaria infection and maternal
malnutrition. WHO policy for malaria
prevention during pregnancy includes
insecticide-treated bed nets, intermittent
preventive treatment during pregnancy
(IPTp), and prompt and effective case man-
agement.9 Intermittent preventive treatment
during pregnancy may also prevent LBW by
preventing other infections because of its
antibacterial properties, and by possible im-
pacts on maternal nutritional status.6 Cur-
rently, IPTp is recommended as repeated
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cern, affecting more than 25 million infants 
annually.1,2 Low birth weight is associated 
with a marked increase in infant mortality and 
contributes to long-term morbidity.1 In 2012, 
the World Health Organization (WHO) 
endorsed a target of 30% reduction in the 
incidence of LBW by 2025. As of 2014, the 
Global Nutrition Report found that there was 
little progress globally toward this goal.3 In-
terventions in low- and middle-income 
countries (LMICs) to prevent LBW have the 
potential to produce substantial public health 
effects, ranging from improved cognitive 
development to enhanced neonatal 
survival.1,2
Two important risk factors for LBW in 
many LMICs are maternal malnutrition and 
malaria infection during pregnancy.4–6 In
a stronger effect on LBW than malaria in-
fection at enrollment in this data set.8
Presence of malaria parasites in peripheral
blood or in the placenta at delivery was
assessed with light microscopic examination
of a Giemsa-stained peripheral or placental
smear or placental histology (active or past
infection) or both.17
Information on how many doses of IPTp
women received was available for 92% of the
study population, and self-reported bed net
ownership at study enrollment was ascer-
tained in 9 of the 13 studies. Bed net own-
ership did not distinguish between untreated
and insecticide-treated bed nets, although
most recent studies will have included the
latter. Currently, the WHO recommends
IPTp with SP, which is what the majority
(64%) of the women received, but some
women in the clinical trials received IPTp
with SP plus azithromycin (16%), SP plus
chloroquine (15%), or dihydroartemisinin-
piperaquine (5%).9 We used MUAC at study
enrollment as our primary measure of ma-
ternal malnutrition, categorizing women
with an MUAC less than 23 centimeters as
malnourished.18 In a sensitivity analysis, we
used gestational age–adjusted BMI less than
18.5 as an alternative anthropometric in-
dicator ofmalnutrition.We adjustedmaternal
weight measured in the second or third tri-
mesters by using a cubic regression model to
account for gestational weight gain.19
Population Intervention Effects
Table 1 and Table A (available as a sup-
plement to the online version of this article at
http://www.ajph.org) describe a series of
contrasts between observed and counterfac-
tual population distributions of malaria in-
fection, IPTp dosage, bed net ownership, and
MUAC. The first 2 contrasts compare the risk
of LBW (1) if the population were all infected
with malaria at delivery or (2) given the
observed distribution of malaria infection,
both comparedwith if none of the population
had been infected. Although not based on
a specific antimalarial intervention, these
contrasts inform on the etiologic effect of
malaria infection at delivery and provide a best
estimate about what would happen if malaria
infection at delivery in the study populations
was completely eliminated. In a sensitivity
analysis, we explored using an aggregate
measure of malaria infection during preg-
nancy, “any malaria,” defined as a positive
microscopy test, rapid diagnostic tests, or
polymerase chain reaction at enrollment,
delivery, or during pregnancy (in 5 studies
with repeat malaria diagnostics throughout
pregnancy). To better guide policies for
specific evidence-based interventions, we also
assessed the impact of scaling up existing
malaria-prevention efforts implemented in
the pooled studies, specifically (1) bed net
ownership and (2) IPTp during pregnancy
(Table 1 and Table A, scenarios 3 and 4).
We took a similar approach for estimating
population-level contrasts for distribution of
lowMUAC, first comparing the risk of LBW
if all women had MUAC less than 23 cen-
timeters, and second comparing the observed
distribution of malnutrition, to the study
population if all women had MUAC at or
more than 23 centimeters (Table 1 and Table
A, scenarios 5 and 6). It is unrealistic to expect
that an intervention could increase the
MUAC of all malnourished women.
Therefore, we also simulated a hypothetical
intervention that would reduce the preva-
lence of low MUAC at study enrollment in
each separate study to 5% (the lowest prev-
alence of malnutrition from any of our
studies). In a sensitivity analysis, an equivalent
approach was takenwhenwe used gestational
age–adjusted BMI to define malnutrition.
Statistical Analysis
We used the parametric g-formula to
estimate the aforementioned population
intervention effects.20,21 The parametric
g-formula, which has also been described as
a substitution estimator by Ahern et al.,22
allows estimation of how the distribution of
LBW would be different if we were able to
alter malaria infection at delivery, the number
of doses of IPTp received during pregnancy,
the level of bed net ownership, and the
prevalence of low MUAC.
First, we modeled the effect of each ex-
posure (malaria, malnutrition, bed net own-
ership, or IPTp dosage) on LBW. We used
logistic regression models, with control for
known and measured confounders, and
generalized estimating equations to account
for within-study correlation. We determined
confounders from a causal directed acyclic
graph23 based on previous literature on the
sulfadoxine and pryimethamine (SP) doses at 
least a month apart, starting in the second 
trimester,9 but before 2007, only 2 doses of 
IPTp were recommended. Consistent with 
the lack of progress toward LBW reduction 
reported by the Global Nutrition Report, in 
2013, an estimated 43% of 35 million eligible 
pregnant women did not receive any doses of 
IPTp.10–12 The WHO endorses balanced 
energy and protein dietary supplementation 
during pregnancy among undernourished 
populations; however, interventions that 
would ameliorate poor nutrition before 
conception have received less focus.2,13
The objectives of this study were 2-fold. 
First, we aimed to estimate the impact of 
implementing hypothetical targeted antima-
larial interventions and reductions in the 
prevalence of low midupper arm circumfer-
ence (MUAC; a proxy for malnutrition) on 
population-level estimates of LBW. Second, 
we aimed to examine whether the introduction 
of any combination of these hypothetical tar-
geted interventions might meet the WHO goal 
of a 30% reduction in the incidence of LBW.
METHODS
The study population comprised 14 633 
live birth pregnancies among women en-
rolled in 1 of 13 studies conducted from 1996 
to 2015 in sub-Saharan Africa (7 countries) 
and the Western Pacific (1 country).14
Outcome and Exposures
The main outcome of interest was LBW. 
Every study measured birth weight within 1 
week of delivery, and birth weights measured 
after 24 hours (13% of weights) were adjusted 
by using a regression model to account for 
changes in weight during the first week of 
life.15 In a sensitivity analysis, we excluded 
weights measured after 24 hours. We con-
sidered 2 secondary outcomes: small-for-
gestational age (a birth weight less than the 
10th percentile of the INTERGROWTH-
21st reference) and preterm birth (gestational 
age < 37 weeks), among a subset of studies 
with ultrasound-dated gestational age.16 
Malaria diagnostics at study enrollment and 
delivery were available; however, this analysis 
focused on malaria infection at delivery 
because malaria infection at delivery had
Second, we “set” (i.e., coded) the expo-
sure to the level specified for the particular
hypothesized intervention (Table 1 andTable
A). With this exposure set (sometimes
counter to the fact of the observed exposure),
we predicted the probability of having a LBW
infant for each individual.
Third, we averaged the imputed proba-
bilities for having a LBW infant for each
individual across the population, for each set
level of exposure. Comparison of the average
outcomes for the different set exposure
provides us with a population-standardized
risk difference (RD) for LBWwhen changing
exposure prevalence. We estimated the
number needed to treat for each contrast of set
exposures as the reciprocal of the absolute
value of the RD. We calculated confidence
intervals (CIs) by using a nonparametric
bootstrap (200 samples with replacement
from original data set).24
RESULTS
Characteristics of the 14 633 women
participating in the 13 M3 studies have been
reported previously and are included in Table
B, available as a supplement to the online
version of this article at http://www.ajph.
org.8 As illustrated in Figure 1, 2312 (20%) of
the 11 826 women with malaria diagnostics
were infected with malaria at delivery and
1224 (14%) of the 8963 women withMUAC
measured were malnourished at enrollment.
Themedian gestational age at enrollment was
20 weeks (interquartile range = 17–24).
These prevalences varied greatly by study site,
with the prevalence of malaria at delivery
ranging from less than 1% (0.3%) to 57% and
the prevalence of malnutrition ranging from
5% to 54% (Table B). The median number of
IPTp doses among the 12 280 women with
IPTp dosage information was 1 (interquartile
TABLE 1—Population Average Causal Effects, Population Attributable Effects, and Generalized Intervention Effects for the Risk of Low Birth
Weight Associated With Malaria Infection and Malnutrition During Pregnancy: Africa and Western Pacific, 1996–2015
Exposure(s) Contrasts Intervention
Malaria interventions
Malaria infection at delivery Population average causal effect: the population with everyone
infectedwithmalaria at delivery comparedwith the population of
women with no infection
NA
Malaria infection at delivery Population attributable effect: the observed distribution of
malaria infection at delivery compared with the population of
women with no infection
Hypothetical complete and instant eradication ofmalaria infection
at delivery
Bed net ownership at enrollment Population attributable effect: the observed distribution of bed
net ownership compared with the population of women in which
everyone owns a bed net
Scaling up of existing bed net intervention
Number of IPTp doses Generalized intervention effect: the observed distribution of IPTp
doses compared with the population in which (1) everyone has at
least 2 doses of IPTp, (2) everyone has at least 3 doses of IPTp, or
(3) at least 80% of the study population has at least 3 doses of IPTp
Scaling up of existing IPTp interventions
Malnutrition interventions
Malnutrition at enrollment Population average causal effect: the population with everyone
malnourished at enrollment compared with the population of
women with no malnutrition
NA
Malnutrition at enrollment Population attributable effect: the observed distribution of
malnutrition (MUAC< 23 cm) compared with the population of
women with no malnutrition
Hypothetical complete and instant eradication of malnutrition
before pregnancy or in early pregnancy
Malnutrition at enrollment Generalized intervention effect: the observed distribution of
malnutrition (MUAC< 23 cm) compared with the population in
which only 5% of each separate study population is malnourished
Hypothetical intervention with a nonspecific mechanism that
would reduce malnutrition prevalence in each study in M3 to 5%
(prevalence in FSP/MISAME-Burkina Faso study)
Note. FSP/MISAME=Micronutriments-Sante de la Mere et de l’Enfant; IPTp = intermittent preventive therapy during pregnancy; LBW= low birth weight;
M3=Maternal Malaria and Malnutrition Initiative; MUAC=midupper arm circumference; NA= not applicable. For example, the second scenario depicts
the population attributable effect for malaria infection at delivery, comparing the risk of LBW under the observed distribution of malaria infection at delivery
in the study population to the risk under a counterfactual setting in which there is hypothetical complete and instant eradication of malaria.
relationship between covariates. Known 
confounders for the malaria–LBW relation-
ship were study site, maternal age, gravidity, 
rural versus urban residence, malnutrition 
(MUAC when available, otherwise BMI), 
HIV infection, anemia at enrollment, malaria 
infection at enrollment, and the number of 
IPTp doses. Confounders for the malnutrition–
LBW relationship were study site, maternal 
age, gravidity, rural versus urban residence, 
anemia at enrollment, and HIV infection. 
Confounders for the bed net–LBW relation-
ship were study site, rural versus urban resi-
dence, gravidity, and number of IPTp doses. 
Confounders for the IPTp–LBW relationship 
were study site, HIV infection, bed net own-
ership, rural versus urban residence, and gra-
vidity. We conducted a complete case analysis 
for each model, and the sample sizes for each 
analysis depended on the availability of data on 
relevant variables.
everyone owned a bed net was 0.3% (95%
CI = –0.3%, 0.8%; Table 2 and Table C).
The RD for 2 or more doses of IPTp
compared with the observed distribution
was modest (0.9%; 95% CI = –0.8%, 1.7%),
but the effect for increasing the dosage to 3 or
more doses for all women was markedly
stronger (RD= 3.0%; 95% CI = 1.7%, 4.0%;
number needed to treat: 33; 95% CI = 25,
60). This number needed to treat suggests
that increasing the IPTp dosage to 3 or more
doses in 33 pregnant women would result in
1 fewer infant born LBW. A similar increase
for 80% of the study population also pro-
duced a substantial impact on LBW (RD=
2.1%; 95% CI=1.0%, 2.7%). These results did
not qualitatively change when we excluded
women with other IPTp regimens (i.e., SP
plus azithromycin, SP plus chloroquine, or
dihydroartemisinin-piperaquine; RD=
3.2%; 95% CI= 1.3%, 4.4%) and when
we excluded infants with birth weight
measured after 24 hours (Table D, available as
a supplement to the online version of this
article at http://www.ajph.org).
The risk difference for LBW when we
compared the population if everyone had low
MUAC at study enrollment versus if all of the
population had MUAC of 23 or more cen-
timeters was 4.0% (95% CI= 3.0%, 5.1%;
Table 2 and Table C). The risk differences for
LBW were smaller when we compared the
observed distribution of MUAC with the
population had there been no malnutrition
(RD=0.3%; 95% CI= 0.2%, 0.4%) or with
the population in which only 5% of each
study was malnourished (RD=0.2%;
95% CI= 0.2%, 0.3%). The population-
standardized risk differences when we used
BMI as an anthropometric indicator of ma-
ternal malnutrition were similar but weaker
(Table E, available as a supplement to the
online version of this article at http://www.
ajph.org).
DISCUSSION
We calculated estimates for the potential
impact of interventions that reduce malaria
infection at delivery, including scale-up of
bed net ownership and IPTp during preg-
nancy and interventions to improve maternal
nutritional status among malnourished
women (according to MUAC measured at
first antenatal visit) on the risk of delivering
a LBW infant. We combined data from 13
studies in malaria-endemic countries in Africa
and the Western Pacific. Calculation of
interventional effects is rarely done in epi-
demiological studies, despite the utility of
such results from a policy and public health
perspective.21,25–27 Overall, these results
showed that increasing uptake of IPTp to 3 or
more doses could markedly reduce the
number of infants born with LBW in
malaria-endemic countries. If all women
received 3 or more doses of IPTp, the in-
cidence of LBWwould be reduced from9.9%
to 6.9%, a 3.0% absolute reduction in LBW
incidence and a 30% (95% CI= 16%, 40%)
relative reduction, matching the WHO 2025
Global Nutrition Target of a 30% reduction
in LBW.1 Even 80% coverage of 3 or more
doses was estimated to result in a 21% (95%
CI= 9%, 28%) relative reduction in LBW.
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Note. IPTp = intermittent preventive therapy during pregnancy; MUAC=midupper arm circumference. Malaria
infection at delivery: n = 11 826; 3 or more doses of IPTp: n = 12 280; bed net ownership at study enrollment:
n = 8516; and low maternal MUAC: n = 8963.
FIGURE 1—Distribution of Malaria Infection at Delivery, Intermittent Preventive Therapy
During Pregnancy, Bed Net Ownership at Study Enrollment, and Low Midupper Arm
Circumference Among Women in the Maternal Malaria and Malnutrition (M3) Initiative:
Africa and Western Pacific, 1996–2015
range = 0–6), and 5260 (62%) of the 8516 
women reported owning a bed net (Figure 1). 
The prevalence of LBW was 9% (range = 5%–
15%). Among 9 studies with ultrasound-dated 
gestational age, the prevalence of small-for-
gestational age was 19% (range = 13%–25%) 
and the prevalence of preterm birth was 11%
(range = 3%–20%).
As reported in Table 2 and Table C
(available as a supplement to the online version 
of this article at http://www.ajph.org), the RD 
for LBW when we compared the population 
in which everyone was infected with malaria 
at delivery with that in which no one was 
infected was 2.0% (95% CI = 0.8%, 3.4%). 
The population-attributable RD was smaller 
(RD = 0.5%; 95% CI = 0.2%, 0.8%) because it 
compared the observed prevalence of malaria 
(only 20% of participants were infected) to 
complete elimination of malaria infection.
The RD for the comparison of observed 
bed net ownership to the population had
main malaria analysis, but a sensitivity analysis
examining the effect of any malaria infection
detected during pregnancy found weaker
intervention effects than our analysis of
malaria infection at delivery, although repeat
malaria diagnostics were not available for all
studies (Table F, available as a supplement to
the online version of this article at http://
www.ajph.org).
An alternative hypothesis is that the ap-
parent effect of IPTp may be attributable to
mechanisms additional to the prevention of
malaria. As it is a broad-spectrum antibiotic,
SP may improve LBW through clearance of
other pathogens associated with fetal growth
restriction and preterm birth and may de-
crease chronic maternal inflammation.28 In
a sensitivity analysis, increased doses of IPTp
had a greater effect on preventing preterm
birth than small-for-gestational age, which
supports the hypothesis that IPTp is func-
tioning to clear pathogens that can cause
preterm birth (Table G, available as a sup-
plement to the online version of this article at
http://www.ajph.org).
The intervention estimates for IPTp did not
account for regional drug resistance,whichcould
have biased our findings; however, previous
TABLE 2—Estimated Population-Level Low Birth Weight Risk Differences for Malaria Infection at Delivery, Bed Net Ownership, Intermittent
PreventiveTherapyDuringPregnancyDosage, andLowMidupperArmCircumferenceAmongWomen in theMaternalMalaria andMalnutrition
(M3) Initiative: Africa and the Western Pacific, 1996–2015
Contrast Risk of LBW, % Risk Difference, % (95% CI) No. Needed to Treat (95% CI)
Malaria infection at delivery (n =11826 [2312 infected])
Population average causal effect
All exposed 9.8 2.0 (0.8, 3.4)
None exposed 7.7
Population attributable effect
Observed 8.2 0.5 (0.2, 0.8) 210 (130, 543)
None exposed 7.7
Bed net ownership (n =8516 [5260 owned bed net])
Population attributable effect
Observed 9.5 0.3 (–0.3, 0.8) 396 (–320, 119)a
All exposed 9.3
IPTp dosage (n =12280 [average 1.5 doses])
Population attributable effect
Observed (n = 2935 [24%] with ‡ 3 doses) 9.9
All ‡ 2 doses 9.0 0.9 (–0.8, 1.7) 115 (–124, 61)a
All ‡ 3 doses 6.9 3.0 (1.7, 4.0) 33 (25, 60)a
80% of each study 3+ doses 7.8 2.1 (1.0, 2.7) 48 (37, 100)a
Maternal malnutrition (n =8963 [1224 with low MUAC])
Population average causal effect
All exposed 13.6 4.0 (3.0, 5.1)
None exposed 9.6
Population attributable effect
Observed 9.9 0.3 (0.2, 0.4) 312 (243, 424)a
None exposed 9.6 43 (34, 63)b
Generalized intervention effect
Observed 9.9 0.2 (0.2, 0.3) 446 (336, 579)a
Exposure reduced to realistic lower bound (5%)c 9.7 61 (47, 90)b
Note. CI = confidence interval; IPTp = intermittent preventive therapy during pregnancy; LBW= low birth weight; MUAC=midupper arm circumference.
aNumber needed to treat, assuming an intervention that is administered to all women.
bNumber needed to treat, assuming an intervention that is administered to women who were malnourished at baseline.
cThe lowest prevalence of malnutrition (MUAC < 23 cm) within the pooled M3 data set was observed in the Intermittent Screening and Treatment or
Intermittent Preventive Treatment for the Control of Malaria in Pregnancy (STOPMIP)-Kenya cohort (5%).
infection at delivery, increasing bed net 
ownership to 100%, or abolishing low 
MUAC at study enrollment had a less 
than 1% reduction on the risk for LBW.
The hypothetical effects for IPTp were 
stronger than the estimated effect of complete 
elimination of malaria infection at delivery, 
which is counterintuitive if one assumes that 
IPTp prevents LBW solely through treating 
and preventing malaria infection. One ex-
planation might be that increased IPTp 
coverage would control malaria through 
much of pregnancy and not just at delivery. 
This was not something we captured in our
IPTp dosage even when accounting for SP
resistance.29,30
Whereas scaling up IPTp had notable
impacts on LBW incidence, the population
attributable effect for bed net ownership was
weak: we estimated that 100% uptake of bed
net ownership would only result in a 0.3%
absolute reduction in LBW prevalence com-
pared with current levels over all studies in this
cohort. However, in our pooled data set,
62% of women with available information
reported owning a bed net at enrollment.
Coverage is likely lower among pregnant
women outside of a research setting: in 2010,
insecticide-treated bed net coverage in sub-
Saharan Africa was only 41%.10,11 If bed net
ownership is overestimated, the actual pop-
ulation intervention estimate is likely greater
than we estimated. In addition, although we
adjusted our model for study site, we did not
have more detailed information on malaria
transmission, regional insecticide resistance,
actual bed net usage, and whether the bed nets
were untreated or insecticide-treated, all of
which may influence the validity of our re-
sults. Given the limitations surrounding our
measurement of bed net usage, we urge
caution in the interpretation of the bed net
results, emphasizing that insecticide-treated
bed nets remain a valuable tool for preventing
malaria and improving fetal development in
malaria-endemic countries.35 However, the
weak population attributable effect for bednets
is aligned with evidence of increased in-
secticide resistance in many regions of sub-
Saharan Africa.36
For malaria, we were able to use in-
formation on real interventions (IPTp and
bed nets), but we were unable to assess a real
nutritional intervention, relying instead on
a hypothetical intervention that affected
maternal MUAC. Although low MUAC at
study enrollment was a strong predictor of
LBW, our intervention effects illustrate that
a hypothetical periconceptional intervention
that would completely or partially reduce the
prevalence of MUAC by the first antena-
tal care visit would have only minor
population-level impacts on LBW. Because
our nutritional assessments were made at
antenatal enrollment, our nutrition models
required the assumption that an interven-
tion could be implemented that would
target malnutrition before pregnancy or in
early pregnancy. For example, an effec-
tive community-based antimalnutrition























Prevalence of 3+ IPTp, %
Note. DRC=Democratic Republic of Congo; IPTp = intermittent preventive therapy during pregnancy;
ISTp = Intermittent Screening and Treatment; ITN = Insecticide-Treated Bed Nets; LAIS = Lungwena Antenatal
Intervention Study; PNG=PapuaNewGuinea; STOPMIP = Intermittent Screening and Treatment or Intermittent
Preventive Treatment for the Control of Malaria in Pregnancy; STOPPAM=Strategies to Prevent Pregnancy
Associated Malaria.
FIGURE2—ThePopulationAttributableEffectof Increasing IntermittentPreventiveTherapy
During Pregnancy Dosage to at Least 3 Doses for All Pregnancies, Stratified by the
Prevalence of at Least 3 Doses of IPTp: Africa and Western Pacific, 1996–2015
studies have found that IPTp–SP remains 
associated with reductions in LBW even 
in areas of SP resistance.29,30 In addition, 
women who more frequently access ante-
natal care, and so receive more doses of 
IPTp, are potentially healthier because of 
associated health-promoting behaviors and 
related socioeconomic status.31
Limitations
Our inability to control for these potential 
unmeasured confounders and selection biases 
indicates that our intervention effects may be 
biased and that the impact of IPTp may not be 
as great as we have estimated. Unmeasured 
healthy behaviors that are promoted or in-
terventions that are provided at the same 
antenatal care visits as SP provision may be 
reducing the risk of LBW instead of SP; 
however, previous studies that controlled for 
the number of antenatal visits were consistent 
with an effect of SP that is independent of the 
number of antenatal visits.32,33 Further studies 
are warranted to elucidate the mechanisms of 
action for SP and to untangle the effects of 
increased dosage from the potential selection 
bias related to more frequent antenatal care.
In addition, women that did not have 
information on the number of IPTp doses 
were on average younger, and had lower 
prevalences of anemia, malaria infection, and 
low MUAC; only analyzing women with 
measured IPTp could have led to selection 
bias if these factors modify the relationship 
between IPTp and LBW (Table H, available 
as a supplement to the online version of this 
article at http://www.ajph.org).
Benefits of Interventions
Despite these limitations, these findings are 
consistent with previous evidence on the 
importance of multiple doses of IPTp during 
pregnancy.30,34 Our estimates agree with 
a mathematical model that estimated that 
215 000 (95% credible interval = 128 000, 
318 000) LBW deliveries in Africa in 2015 
could have been prevented by women taking 
IPTp–SP during at least 3 antenatal care 
visits.30 Despite the evidence regarding the 
benefits of IPTp, coverage is presently in-
adequate.10–12 Concerns around SP drug 
resistance have contributed to this low level of 
coverage; however, the synthesis of current 
evidence supports the benefits of increasing
campaign targeted at women of reproductive
age could potentially produce the changes in
maternal malnutrition that we model. Future
studies may wish to estimate impacts of hy-
pothetical nutritional interventions that
would improve gestational weight gain
during pregnancy, which is a strong predictor
of birth weight.37
In all analyses, the extent of unmeasured
confounding is unknown. Potential un-
measured confounders include helminth
infection, sexually transmitted infections,
environmental pollutants, or micronutrient
deficiencies. In addition, all of the intervention
effects reported are a function of background
prevalences of the exposure of interest in each
analysis; thus, they may not be generalizable to
settings with dramatically different baseline
prevalences. Figure 2 and Figure A (available as
a supplement to theonline version of this article
at http://www.ajph.org) illustrate that the
LBW risk difference associated with increasing
IPTp dosage to 3 or more doses for all preg-
nancies is greatest among studies with low
levels of IPTp coverage and high levels of
malaria prevalence at delivery.
Public Health Implications
In conclusion, of the interventions we
evaluated, 3 or more doses of IPTp appear to
offer the greatest potential for achieving the
WHO’s Global Nutrition Target of a 30%
reduction in LBW by 2025. Although the
IPTp estimates were notably strong, hypo-
thetical interventions to eliminate malaria
infection at delivery or to increase MUAC
at study enrollment did not appear to have
strong impacts on population-level incidence
of LBW. Although we cannot discount po-
tential unmeasured confounding and selec-
tion bias of the IPTp estimates, our findings
suggest that IPTp–SP prevents LBW through
mechanisms beyond malaria treatment and
prevention.
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